Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Add an action for EOCN.US, or sign in to see your action list.
| Name | Title | Year Born |
|---|---|---|
| Mr. Allen Baharaff | Co-Founder, President, CEO & Chairman | 1965 |
| Mr. Doron Cohen | Chief Financial Officer | 1967 |
| Mr. Guy Nehemya | COO & Data Protection Officer | 1985 |
| Mr. Yohai Stenzler CPA | Chief Accounting Officer | 1983 |
| Dr. Liat Hayardeny MBA, Ph.D. | Chief Scientific Officer | 1967 |
| Dr. Tali Gorfine | Medical Consultant | 1970 |
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.